Health-related quality of life during sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: A multicenter phase II study of the North Eastern German Society of Gynecological Oncology

Anticancer Research

Volumn 32, Issue 9, 2012, Pages 3969-3976

  Richter, Rolf ^a   Oskay Oezcelik, Guelten ^a   Chekerov, Radoslav ^a   Pilger, Adak ^a   Hindenburg, Hans Joachim ^b   Sommer, Harald ^c   Camara, Oumar ^d   Keil, Elke ^e   Einenkel, Jens ^f   Sehouli, Jalid ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b North Eastern German Society of Gynaecological Oncology (NOGGO)   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d JENA UNIVERSITY HOSPITAL   (Germany)

^e Park Clinic Berlin   (Germany)

^f UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Clinical phase II trial; Dose dense chemotherapy; Ovarian cancer; Quality of life; Sequential first line chemotherapy

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CONSTIPATION; CYTOREDUCTIVE SURGERY; DIARRHEA; DYSPNEA; FATIGUE; FEMALE; FEMALE SEXUAL DYSFUNCTION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OVARY CANCER; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; QUALITY OF LIFE;

EID: 84866980284     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Greimel ER, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F and du Bois A: Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. J Clin Oncol 24: 579-586, 2006.
2. Bezjak A, Tu P, Bacon M, Osoba D, Zee B, Stuart G, Roy JA, Piccart M and Eisenhauer E: Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. J Clin Oncol 22: 4595-4603, 2004.
3. Arriba LN, Fader AN, Frasure HE and von Gruenigen VE: A review of issues surrounding quality of life among women with ovarian cancer. Gynecol Oncol 119: 390-396, 2010.
4. Sullivan M: The new subjective medicine: Taking the patient's point of view on health care and health. Soc Sci Med 56: 1595-1604, 2003.
5. Greimel ER, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F, Pujade-Lauraine E and du Bois A for the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGOOVAR) and the Groupe d'Investigateurs Nationaux pour les Etudes des Cancers de l'Ovaire (GINECO): Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials. Support Care Cancer 19: 1421-1427, 2011.
6. Oskay-Ozcelik G, Chekerov R, Sommer H, Keil E, Einenkel J, Pfisterer J, Lorenz-Schlüter C, Lichtenegger W, Camara O and Sehouli J: Sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: Results of a multicenter phase II study of the Northeastern German Society of Gynecological Oncology. Gynecol Oncol 116: 317-322, 2010.
7. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K and Noda K; Japanese Gynecologic Oncology Group: Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial. Lancet 374(9698): 1331-8, 2009.
8. Fujiwara K, Aotani E, Hamano T, Nagao S, Yoshikawa H, Sugiyama T, Kigawa J, Aoki D, Katsumata N, Takeuchi M and Suzuki M: A randomized phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer. Jpn J Clin Oncol 41: 278-282, 2011.
9. Penson R, Cella D and Wenzel L: Quality of life in ovarian cancer. J Reprod Med 50: 407-416, 2005.
10. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCJM, Kaasa S, Klee MC, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw KCA, Sullivan M and Takeda F: The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365-376, 1993.
11. Cull A, Howat S, Greimel E, Waldenstrom AC, Arraras J, Kudelka A, Chauvenet L and Gould A on behalf of the EORTC Quality of Life Group and the Scottish Gynaecological Cancer Trials Group: Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report. Eur J Cancer 37: 47-53, 2001.
12. Osoba D, Zee B, Pater J, Warr D, Kaizer L and Latreille J: Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 3: 353-364, 1994.
13. Schwarz R and Hinz A: Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer 37: 1345-1351, 2001.
14. Greimel E, Bottomley A, Cull A, Waldenstrom AC, Arraras J, Chauvenet L, Holzner B, Kuljanic K, Lebrec J and D'haese S on behalf of the EORTC Quality of Life Group and the Quality of Life Unit: An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer 39: 1402-1408, 2003.
15. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D and Bottomley A on behalf of the EORTC Quality of Life Group: The EORTC QLQ-C30 Scoring Manual (3rd Edition). European Organisation for Research and Treatment of Cancer, Brussels 2001.
16. Luckett T, King M, Butow P, Friedlander M and Paris T: Assessing health-related quality of life in gynecologic oncology: A systematic review of questionnaires and their ability to detect clinically important differences and change. Int J Gynecol Cancer 20: 664-684, 2010.
17. von Gruenigen VE, Frasure HE, Jenison EL, Hopkins MP and Gil KM: Longitudinal assessment of quality of life and lifestyle in newly diagnosed ovarian cancer patients: The roles of surgery and chemotherapy. Gynecol Oncol 103: 120-126, 2006.
18. Koensgen D, Oskay-Oezcelik G, Katsares I, Walle U, Klapp C, Mustea A, Stengel D, Porzsolt F, Lichtenegger W and Sehouli J on behalf of the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO) working group "Quality of life": Development of the Berlin Symptom Checklist Ovary (BSCL-O) for the measurement of quality of life of patients with primary and recurrent ovarian cancer: Results of a phase I and II study. Support Care Cancer 18: 931-942, 2010.
19. Penson RT, Wenzel LB, Vergote I and Cella D: Quality of life considerations in gynecologic cancer. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 95(Suppl 1): S247-257, 2006.
20. Lakusta CM, Atkinson MJ, Robinson JW, Nation J, Taenzer PA and Campo MG: Quality of life in ovarian cancer patients receiving chemotherapy. Gynecol Oncol 81: 490-495, 2001.
21. Greimel E, Daghofer F and Petru E: Prospective assessment of quality of life in long-term ovarian cancer survivors. Int J Cancer 128: 3005-3011, 2010.
22. Stewart DE, Wong F, Duff S, Melancon CH and Cheung AM: "What doesn't kill you makes you stronger": An ovarian cancer survivor survey. Gynecol Oncol 83: 537-542, 2001.
23. Mirabeau-Beale KL, Kornblith AB, Penson RT, Lee H, Goodman A, Campos SM, Duska L, Pereira L, Bryan J and Matulonis UA: Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecol Oncol 114: 353-359, 2009.
24. Gonçalves V: Long-term quality of life in gynecological cancer survivors. Curr Opin Obstet Gynecol 22: 30-35, 2010.
25. Liavaag AH, Dørum A, Fosså SD, Tropé C and Dahl AA: Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: How lucky are the lucky ones? J Clin Oncol 25: 2049-2056, 2007.
26. Wenzel LB, Donnelly JP, Foweler JM. Habbal R, Taylor TH, Aziz N and Cella D: Resilience, reflection, and residual stress in ovarian cancer survivorship: A Gynecologic Oncology Group study. Psychooncology 11: 142-153, 2002.
27. von Gruenigen VE, Huang HQ, Gil KM, Gibbons HE, Monk BJ, Rose PG, Armstrong DK, Cella D and Wenzel L: Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials. Cancer 115: 4857-4864, 2009.
28. Easterlin RA: Building a better theory of well-being. In: Economics and Happiness: Framing the Analysis. Bruni L and Porta PL (eds.). Oxford University Press, New York, pp. 69-64, 2006.
29. Pignata S, Ballatori E, Favalli G and Scambia G: Quality of life: Gynaecological cancers. Ann Oncol 12(Suppl 3): S37-42, 2001.
30. Liavaag AH, Dørum A, Bjøro T, Oksefjell H, Fosså SD, Tropé C and Dahl AA: A controlled study of sexual activity and functioning in epithelial ovarian cancer survivors. A therapeutic approach. Gynecol Oncol 108: 348-354, 2008.
31. Donovan K, Sanson-Fisher RW and Redman S: Measuring Quality of Life in Cancer Patients. J Clin Oncol 7: 959-968, 1989.
32. Le T, Hopkins L and Kee Fung MF: Quality of life assessment during adjuvant and salvage chemotherapy for advance stage epithelial ovarian cancer. Gynecol Oncol 98: 39-44, 2005.
33. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ and Liang SX on behalf of the Gynecologic Oncology Group: Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365: 2473-83, 2011.
34. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK and Oza AM on behalf of the ICON7 Investigators: A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365: 2484-96, 2011.